Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + rituximab versus bendamustine + rituximab in previously untreated transplant-ineligible mantle cell lymphoma
CTR20211594Phase 3Active
- Sponsor
- BeiGene
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) comparing zanubrutinib + rituximab with bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival by independent central review. Started Sep 2020; status: active.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20211594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211594.